[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemodialysis":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,55,90,112,141,169,199,226,251,274,302,321,348,370,405,429,459,488,514,539,559,589,612,638,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100645108","randomized-cross-over-comparison-of-medium-cut-off-and-high-flux-hemodialysis-membranes-100645108",false,"NCT07679763","Randomized Cross-Over Comparison of Medium Cut-Off and High-Flux Hemodialysis Membranes","Randomized Cross-Over Evaluation of Medium Cut-Off and High-Flux Hemodialysis Membranes on Inflammation and Cardiovascular Function in Maintenance Hemodialysis Patients","MCO-HD","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Receiving maintenance hemodialysis for at least 6 months.\n* Clinically stable and receiving thrice-weekly hemodialysis.\n* Able to comply with study procedures, questionnaires, and scheduled assessments.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute infection at screening or enrollment.\n* Major surgery within the previous 3 months.\n* Active malignancy requiring ongoing treatment.\n* Terminal illness with limited life expectancy.\n* Physical or cognitive impairment preventing completion of study procedures or questionnaires.\n* Inability or unwillingness to provide written informed consent.","ALL","18 Years","80 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","Patients receiving maintenance hemodialysis are at increased risk of cardiovascular disease, chronic inflammation, endothelial dysfunction, and impaired quality of life. Medium cut-Off (MCO) hemodialysis membranes have been developed to enhance the removal of middle-molecular-weight uremic toxins compared with conventional high-flux membranes, which may improve inflammatory status and cardiovascular health.\n\nThe aim of this study is to compare the effects of MCO and high-flux hemodialysis membranes on inflammatory biomarkers and cardiovascular function in adult patients receiving maintenance hemodialysis. The primary outcomes are changes in serum interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) levels. Secondary outcomes include arterial stiffness assessed by pulse wave velocity (PWV), body composition assessed by Body Composition Monitor (BCM), handgrip strength, and patient-reported outcomes including quality of life, pruritus, and pain scores.\n\nThis is a prospective, randomized, open-label, two-sequence, two-period crossover study conducted at Gazi University Faculty of Medicine. Thirty adult hemodialysis patients will be randomized to one of two treatment sequences. Participants in Sequence A will receive MCO dialysis membranes for the first 3 months followed by high-flux membranes for the next 3 months. Participants in Sequence B will receive high-flux membranes for the first 3 months followed by MCO membranes for the next 3 months. Blood samples and clinical assessments will be performed at baseline, month 3, and month 6.\n\nThe study is expected to provide evidence regarding the effects of different dialysis membrane technologies on inflammation and cardiovascular health and may contribute to optimizing membrane selection in routine hemodialysis practice.",[29,30,31,32],"End Stage Kidney Disease (ESKD)","Hemodialysis","Cardiovascular Diseases (CVD)","Inflammation",[34,35,36,37,38,32,39,40,41],"End-Stage Kidney Disease","High-Flux Hemodialysis","Medium Cut-Off Membrane","Interleukin-6","VCAM-1","Cardiovascular Function","Pulse Wave Velocity","Body Composition Monitor","NOT_YET_RECRUITING","2026-06-30",{"date":45,"type":46},"2026-07-01","ACTUAL",{"date":48,"type":23},"2026-07",{"date":50,"type":23},"2027-01",{"name":52,"class":53},"Gazi University","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100644867","euvolemia-based-assessment-of-pulmonary-hypertension-in-stable-hemodialysis-patients-100644867","NCT07676786","Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients","Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis","EU-PHASE-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* End-stage kidney disease on maintenance HD for ≥ 3 months.\n* Stable clinical condition (no hospitalization in last 30 days).\n* Able and willing to comply with study protocol.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere left-sided valvular disease.\n* Active pulmonary or cardiac decompensation.\n* Persistent hypervolemia after completion of the volume assessment and correction phase\n* Inability to undergo echocardiography or bioimpedance assessment.\n* Acute infection or inflammatory condition at the time of enrollment.\n* Inadequate echocardiographic window preventing reliable assessment",{"count":22,"type":23},"OBSERVATIONAL","Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.\n\nThis prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.\n\nIn participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.\n\nThe study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.",[67,68,69,70,71,30],"Pulmonary Hypertension (PH)","End Stage Kidney Disease (ESRD)","Hemodialysis Patients","Volume Overload","Volume Assessment",[73,30,34,74,70,75,76,77,78,79,80,81],"Pulmonary Hypertension","Euvolemia","Volume Status","Echocardiography","Bioimpedance Spectroscopy","Interdialytic Weight Gain","Vascular Access","Blood Pressure Variability","Lung Ultrasound","2026-06-24",{"date":43,"type":46},{"date":45,"type":23},{"date":86,"type":23},"2027-03-30",{"name":88,"class":53},"Stefan Lujinschi",2,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":54},"100619021","preoperative-hemodialysis-timing-in-patients-with-end-stage-kidney-disease-the-pod-eskd-pilot-trial-100619021","NCT07339202","Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial","POD-ESKD","Inclusion Criteria:\n\n1. Patient is willing to comply with all study procedures for the duration of the study\n2. Patient has a diagnosis of ESKD\n3. Patient initiated hemodialysis at least 90 days prior to the planned surgical procedure\n4. Patient is treated with a stable hemodialysis schedule, defined as an average of 2.5- 3.5 hemodialysis sessions per week in the preceding 4 weeks prior to surgery\n5. Patient is scheduled to undergo nonemergent surgical procedures in the Stanford Health Care system. This includes (but is not limited to):\n\n   * Fistula or graft creation, revision, or removal\n   * Fistulogram\n   * Peritoneal dialysis catheter placement or revision\n   * Lower extremity angiogram (including femoral and iliac vessels)\n   * Lower extremity bypass (including femoral and iliac vessels)\n   * Lower extremity amputation\n   * Lower extremity endarterectomy (including femoral and iliac vessels) Of note, this list of procedures is not exhaustive and other procedures may be considered that meet inclusion criteria and no exclusion criteria, in consultation with the treatment teams involved.\n\nExclusion Criteria:\n\n1. Patient is pregnant\n2. Patient is a prisoner\n3. Patient is \\\u003C 18 years old\n4. The treating clinicians determine that the patient's clinical condition necessitate a specific approach to surgical scheduling or preoperative hemodialysis",{"count":22,"type":23},[26],"The goal of this clinical trial is to evaluate the feasibility of two different preoperative hemodialysis schedules for people with end-stage kidney disease (ESKD) who undergo surgical procedures. The main questions it aims to answer are:\n\nIs it feasible to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis?\n\nIs it safe to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis?\n\nResearchers will compare the two hemodialysis schedules to see if the scheduling and safety profiles are the same.\n\nParticipants will:\n\nAnswer questions about their health up to 4 weeks before and 4 weeks after the surgical procedure.\n\nReceive hemodialysis on the day of the surgical procedure or not, depending on the study treatment assignment.",[101,68,30],"Perioperative Management","RECRUITING","2026-06-08",{"date":105,"type":46},"2026-06-11",{"date":107,"type":46},"2026-05-27",{"date":109,"type":23},"2027-10-15",{"name":111,"class":53},"Stanford University",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100640554","mindfulness-meditation-in-hemodialysis-patients-100640554","NCT07620990","Mindfulness Meditation in Hemodialysis Patients","The Effect of Mindfulness Meditation on Sleep, Stress, and Symptoms in Hemodialysis Patients: A Randomized Controlled Trial","MIND-HD","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years\n* Patients receiving hemodialysis treatment for at least 3 months\n* Patients with cognitive functions suitable for the intervention (dementia score ≥21)\n* Patient without hearing, vision or communication problems\n* Patients without a psychiatric diagnosis\n* Patients able to use a smartphone or tablet\n* Patients not participating in another study\n* Patients not using sleep medication or antipsychotic drugs\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 75 years\n* Patients receiving hemodialysis treatment for less than 3 months\n* Patients with cognitive impairment unsuitable for the intervention (dementia score ≤21)\n* Patient with hearing, vision or communication disabilities\n* Patients diagnosed with psychiatric disorders\n* Patients unable to use a smartphone or tablet\n* Patients participating in another study\n* Patients using sleep medication or antipsychotic drugs","75 Years",{"count":122,"type":23},50,[26],"This randomised controlled study aims to evaluate the effects of mindfulness meditation on sleep quality, perceived stress and symptoms levels ion hemodialysis patients. Participants in the intervention group will receive a 4 week mindfulness meditation program in addition to routine care. Outcomes will be assessed before and after the intervention using validated measurement tools.",[30,126,127,128],"Stress","Sleep Quality","Symptom",[130,30,127,126,128],"Mindfulness Meditation","2026-06-01",{"date":133,"type":46},"2026-06-02",{"date":135,"type":46},"2026-04-15",{"date":137,"type":23},"2026-08",{"name":139,"class":53},"Cyprus Aydin University",4,{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":54},"100628407","modulation-of-gut-microbiota-composition-and-gut-permeability-profiles-by-multispecies-synbiotic-supplementation-in-hemodialysis-patients-100628407","NCT07461233","Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months\n\nExclusion Criteria:\n\n1. Use of probiotic supplements within the last month;\n2. Hospitalization within the past month for acute infections or CKD-related complications;\n3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);\n4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;\n5. Use of antibiotics or immunosuppressive therapy within the preceding three months.",{"count":22,"type":23},[26],"Chronic kidney disease (CKD) patients undergoing maintenance hemodialysis experience profound alterations in their gut microbiota, leading to dysbiosis and increased gut permeability. This disruption facilitates the translocation of endotoxins and gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate into the systemic circulation, contributing to heightened systemic inflammation, cardiovascular disease risk, and accelerated CKD progression.\n\nSynbiotic supplementation, particularly multispecies formulations, has emerged as a promising therapeutic strategy to restore gut microbial balance, enhance intestinal barrier integrity, and reduce the systemic burden of deleterious microbial metabolites. These probiotics potentially improve clinical outcomes by modulating inflammatory pathways and decreasing circulating levels of uremic toxins.\n\nDespite these insights, few clinical trials have comprehensively assessed the effects of multispecies synbiotic on fecal microbiome composition, gut permeability and uremic toxin profiles in hemodialysis patients. This pilot study aims to fill this gap by evaluating the modulatory effects of a 12-week multispecies synbiotic intervention.",[151,152,153,154,30],"Symbiotic","Uremic Toxins","Gut -Microbiota","Gut Permeability",[156,157,158,159,160],"multispecies synbiotic","hemodialysis patients","uremic toxins","gut microbiome","gut permeability",{"date":162,"type":46},"2026-06-03",{"date":164,"type":46},"2026-05-04",{"date":166,"type":23},"2026-12-31",{"name":168,"class":53},"Tungs' Taichung Metroharbour Hospital",{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":54},"100637411","cansolve-20-theme-31-mind-the-gap---dialectical-behavioural-therapy-dbt-skills-training-program-pilot-100637411","NCT07628309","CanSOLVE 2.0 Theme 3.1 Mind the Gap - Dialectical Behavioural Therapy (DBT) Skills Training Program Pilot","CanSOLVE 2.0 Theme 3.1 Mind the Gap: Addressing Mental Health Care Gaps for Canadians Receiving Facility-Based Hemodialysis - Dialectical Behavioural Therapy (DBT) Skills Training Program Pilot Intervention","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Individuals followed in the Manitoba Kidney Health Program at Seven Oaks General Hospital or Health Sciences Centre sites with advanced chronic kidney disease not yet on facility-based hemodialysis but with plans to start within 1 month; OR\n* Individuals followed in the Manitoba Kidney Health Program at the SOGH or HSC sites who have initiated facility-based hemodialysis within the last 90 days\n* Able and willing to attend weekly DBT sessions (either virtually or in-person)\n* Experiencing self-reported psychological distress related to advanced kidney disease or initiation of hemodialysis\n* Deemed eligible to participate by study clinical psychologist\n\nExclusion Criteria:\n\n* Unable to complete intervention due to planned relocation\u002Ftransplant\u002Fmodality change\n* Unable to communicate in English\n* Deemed by hemodialysis unit staff\u002Fphysician\u002Fstudy psychologist to be unable to participate fully in study activities due to:\n\n  * Actively participating in psychiatric care with psychiatric (DSM-5) diagnosis\n  * Requiring referral for psychiatric care as per facility-based HD care provider assessment\n  * Current psychotic symptoms\n  * Cognitive impairment that would limit ability to participate in group or complete homework\n  * Safety risk to staff (e.g. physical aggression)\n  * Antisocial personality disorder or other issues that may limit ability to constructively participate in peer group\n  * Severe comorbid substance use disorder (if present will offer referral to addictions resources or Addictions Psychiatry)",{"count":177,"type":23},35,[26],"The goal of this pilot implementation study is to implement and evaluate a 13-week dialectical behavioural therapy (DBT) skills training program to address challenges to mental health and mental wellbeing in people who have recently started facility-based hemodialysis or those who may start within the next 6-12 months.",[181,182,30,183,184],"Mental Health","Mental Health Care","DIALYSIS SYMPTOMS AND ANXIETY","Health Related Quality of Life",[186,187,188,189],"hemodialysis","mental health","dialysis anxiety","mental well-being","2026-05-29",{"date":192,"type":46},"2026-06-05",{"date":194,"type":46},"2026-03-05",{"date":196,"type":23},"2026-07-15",{"name":198,"class":53},"University of Manitoba",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":24,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":54},"100549776","effects-of-royal-jelly-supplementation-in-chronic-kidney-disease-100549776","NCT06438445","Effects of Royal Jelly Supplementation in Chronic Kidney Disease","Effects of Royal Jelly Supplementation on Inflammation and Cellular Senescence in Chronic Kidney Disease Patients Under Hemodialysis","Inclusion Criteria:\n\n* patients with CKD undergoing hemodialysis for more than 6 months\n* patients with arteriovenous fistula (AVF) as vascular access.\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS","70 Years",{"count":22,"type":23},[26],"The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).",[211,212,30],"Kidney Failure, Chronic","Oxidative Stress",[214,215,216,212],"Cellular Senescence","Renal Dialysis","Renal Insufficiency, Chronic","2026-05-14",{"date":219,"type":46},"2026-05-18",{"date":221,"type":46},"2024-07-30",{"date":223,"type":23},"2027-04-05",{"name":225,"class":53},"Universidade Federal Fluminense",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":233,"sex":18,"minAge":4,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":24,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":54},"100600581","efficacy-of-of-acupuncture-laser-therapy-on-hemodialysis-patients-100600581","NCT07099352","Efficacy of of Acupuncture Laser Therapy on Hemodialysis Patients","Efficacy of of Acupuncture Laser Therapy on Neck Pain Severity and Quality of Life in Hemodialysis Patients","Inclusion Criteria:\n\n-Their mean age will range from (18-65) years old.\n\nExclusion Criteria:\n\n-a failure to take part in more than three light therapy sessions; a kidney transplant; and death.",true,"60 Years",{"count":236,"type":23},60,[26],"This expected prospective randomized control trial study will involve 60 haemodialysis patients with neck pain. The patients in the experimental group (E) will subject, medical treatment besides acupuncture laser therapy. Medical treatment will be used in the control group (C). Pain and quality of life assessment will be used in the assessment of outcome.",[30],[241],"Hemodialysis, Acupuncture Laser Therapy","2026-05-05",{"date":244,"type":46},"2026-05-11",{"date":246,"type":23},"2026-05-01",{"date":248,"type":23},"2026-10-01",{"name":250,"class":53},"Sinai University",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":54},"100580084","assessment-of-a-wearable-ultrafiltration-device-100580084","NCT06832696","Assessment of a Wearable Ultrafiltration Device","Initial Assessment of a Wearable Residual Ultrafiltration Device (RUF-D) to Address Challenges Associated With Inadequate Volume Management in Hemodialysis Patients","RUF-D","Inclusion Criteria:\n\n* At least one of the following:\n\n  1. Average per-session IDWG ≥ 4.0% of dry weight in the last month\n  2. Inability to consistently achieve dry weight with current HD\n  3. Need for additional HD treatments to achieve prescribed dry weight\n* HD sessions three times\u002Fweek\n* Age ≥ 18 years\n* Dialyzing via central venous access\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Active infections\n* Non-compliance to hemodialysis prescription\u002Fschedule",{"count":260,"type":23},18,[26],"Kidney failure is common. In some people the ability of the kidneys to clean poisons out of the blood gets so low they need to be hooked up to a machine three times a week to do it for them. This is called dialysis. Unfortunately, although this treatment removes those waste products, people who need dialysis die much more often than people who don't need dialysis. Dialysis causes extreme stress on the body and leads to many organs being damaged.\n\nRemoving fluid from the body quickly causes the equivalent of repeated little heart attacks or little strokes in the brain. Many patients struggle to tolerate having all the fluid that they have drunk since their last dialysis session removed- without unpleasant symptoms of dangerously low blood pressure (which makes the damage worse).\n\nDialysis treatments can be done more slowly or more often, but that means having to spend a lot more time at the hospital and is difficult for the health system to be able to provide the extra treatment time.\n\nCould extra fluid be removed in between dialysis sessions? Up to now there has not been a way to effectively do this. Investigators have now designed and built an entirely new, very small and very simplified, device that can do part of what a dialysis machine does. It doesn't clean the blood or replace the need for conventional dialysis sessions, but it can provide additional and gentle removal of fluid which wasn't able to be taken off during a standard treatment session.\n\nIf this study is successful, it will be the first time that a wearable device has been successfully built and used to take off extra fluid when dialysis patients are not in the hospital. The ability to do this opens up the possibility of, 1) helping to treat patients (both making people feel better and live longer) who can't tolerate getting off all the fluid in the short 3-4 hours they are on the dialysis machine in the hospital, and 2) helping patients who feel OK having the fluid taken off but are silently being subjected to damage to their organs due to the rapid removal, have reduced damage.",[30,264],"Ultrafiltration",[30,264],"2026-04-28",{"date":268,"type":46},"2026-04-29",{"date":45,"type":23},{"date":271,"type":23},"2027-12-31",{"name":273,"class":53},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":24,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":54},"100634831","pea-fibre-in-hemodialysis-100634831","NCT07544797","Pea Fibre in Hemodialysis","Influencing Microbiota and Uremic Toxins With Pea Fibre Intervention in Nephrology","MUFIN","Inclusion Criteria:\n\n* male and female patients 18-89 years of age\n* chronic hemodialysis treatment minimum 3 months for any kind of kidney disease\n* 2-3 hemodialysis sessions per week\n* expected to continue regular treatment for at least 3 months\n* written informed consent\n\nExclusion Criteria:\n\n* Persons younger than 18 or older than 89 years\n* Clinically relevant infections at the time of the study or within 2 weeks prior to study inclusion\n* Use of immunosuppressive medications, with the exception of glucocorticoids ≤ 5 mg prednisolone equivalent\n* Liver cirrhosis, Child-Pugh stage C\n* Active malignancy, with or without specific oncological therapy\n* Blood transfusion within 4 weeks prior to inclusion, or severe anemia with a current indication for blood transfusion\n* Planned absence (e.g., vacation) for more than 1 week during the study period\n* Pregnancy\n* Intolerance to gluten, eggs, milk, yeast, nuts, or pea protein\n* Missing consent to participate in the study\n* Inability to understand the study content and procedures and to provide informed consent after appropriate explanation\n* Persons institutionalized by court or administrative order\n* Simultaneous participation in another interventional study","89 Years",{"count":284,"type":23},72,[26],"Background and problem Chronic kidney disease (CKD) affects a large share of adults worldwide and is a growing public-health concern. People with advanced CKD can develop \"uremia\", a dangerous build-up of waste products in the blood that the failing kidneys cannot remove. Even when patients receive regular dialysis, many so-called \"uremic toxins\" remain in the body because some of these substances bind tightly to blood proteins and are poorly removed by dialysis. Over 100 uremic toxins have been identified and classified and protein-bound toxins such as Indoxylsulfate and p-Cresylsulfate are especially difficult to clear by dialysis.\n\nSome uremic toxins are linked to heart and blood-vessel disease, inflammation, and worse outcomes in dialysis patients. For example, Indoxylsulfate has been associated with higher mortality, vascular calcification, vessel stiffness and heart failure. Reducing these toxins might therefore improve quality of life and lower cardiovascular risk in people on dialysis.\n\nPurpose of the study The study will test whether adding inner, fermentable pea fiber (a natural prebiotic) to the daily diet of hemodialysis patients can lower blood levels of uremic toxins-especially Indoxylsulfate-and improve related markers of inflammation and cardiovascular risk. The investigators hypothesize that fermentable fibers change gut bacterial composition so that less toxin-forming bacterial metabolism (from amino acids like tryptophan) occurs, thereby reducing the amount of harmful metabolites that reach the blood.\n\nType of study: Randomized, double-blind, controlled trial with two groups. Duration: 8 weeks of intervention. Intervention: Participants will receive daily baked goods (bread, rolls, muffins, scones, pizza bread) that together provide 20 g of pea fiber per day; the control group will receive identical foods without added pea fiber. The fiber mix uses commercially available inner pea-fiber products.\n\nBlood and stool sampling: Blood samples are taken before the intervention, at 4 weeks and at 8 weeks to measure Indoxylsulfate and other toxins, inflammation markers, vitamin D metabolites and cardiovascular risk markers. A subgroup will also provide stool samples to study changes in the gut microbiome.\n\nWho can join Adults aged 18-89 who have been on chronic hemodialysis for at least three months and receive dialysis two to three times per week are eligible. The study excludes people with recent serious infections, advanced liver disease, active cancer, recent blood transfusion, pregnancy, certain food intolerances or inability to consent. Each study arm will include 36 participants.\n\nPrimary and secondary outcomes Primary outcome: Change in blood Indoxylsulfate concentration between the pea-fiber group and the control group.\n\nSecondary outcomes: Levels of other uremic toxins, routine kidney-related blood tests (creatinine, urea, uric acid), electrolytes, vitamin D metabolites, inflammatory markers, lipid markers, FGF23, short-chain fatty acids, sKlotho, and the effect of patient serum on cytokine production in a standard immune cell line. Stool analyses in a subgroup will examine shifts in bacterial groups and metabolic networks.\n\nHow the intervention is delivered and monitored Foods are prepared in a certified bakery and coded so neither participants nor study staff know who receives pea fiber or placebo. To improve adherence, participants choose from a variety of pre-portioned baked items and are advised to spread intake across the day. Unused portions are returned and logged. Dietary recalls and symptom questionnaires are collected to monitor changes in overall diet, appetite and gastrointestinal side effects. Blood draws are timed before dialysis after the long interdialytic interval to standardize measurements.\n\nPotential impact and limitations If fermentable inner pea fibers lower Indoxylsulfate and related toxins, this would support a simple, food-based strategy to reduce toxin burden and possibly cardiovascular risk in dialysis patients. However, previous studies show mixed results depending on the type of fiber used: fermentable fibers (like amylose-rich starch or inulin) have produced beneficial changes in some trials, while non-fermentable fibers did not. Since evidence high-quality randomized trials in dialysis patients is still limited there is the need for this study.",[30,288],"Kidney Failure Chronic",[290,186,291,292,293,294],"prebiotics","pea fibre","indoxylsulfate","kidney failure chronic","uremic toxin",{"date":296,"type":46},"2026-04-22",{"date":246,"type":23},{"date":299,"type":23},"2028-12-31",{"name":301,"class":53},"Martin-Luther-Universität Halle-Wittenberg",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":54},"100611000","phase-2-study-to-evaluate-the-effects-of-av-001-on-hd-induced-brain-injury-100611000","NCT07234890","Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Exploratory Study to Evaluate the Neuroprotective Effects of AV-001 on Hemodialysis-induced Brain Injury Via Cerebrovascular Stabilization in Chronic Hemodialysis Patients","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Male and non-pregnant female patients (\\>18 years old)\n* HD for ≥ 3 months\n* Thrice weekly HD schedule\n\nExclusion Criteria:\n\n* HD \\\u003C90 days\n* Contraindication to MRI\n* Established severe cognitive impairment (Montreal Cognitive Assessment test (MoCA) \\\u003C18 or formal diagnosis of dementia)\n* Previous clinical stroke\n* Pregnancy, breastfeeding, or intending pregnancy\n* Intradialytic hypotension event (defined as: drop in SBP ≥40mmHg + symptoms + intervention) in previous month as evidenced by HD record",{"count":236,"type":23},[311],"PHASE2","Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy.\n\nThis research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation.\n\nIf successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.",[30],{"date":315,"type":46},"2026-04-17",{"date":317,"type":46},"2025-12-16",{"date":271,"type":23},{"name":320,"class":53},"London Health Sciences Centre Research Institute",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100632771","effect-of-pecha-kucha-education-on-fluid-and-diet-adherence-in-hemodialysis-patients-100632771","NCT07518017","Effect of Pecha Kucha Education on Fluid and Diet Adherence in Hemodialysis Patients","Effect of Pecha Kucha-Based Education on Fluid and Dietary Adherence and Clinical Outcomes in Hemodialysis Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Receiving hemodialysis treatment for at least 6 months\n* Aged 18 years or older\n* Literate\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Cognitive or communication impairment\n* Participation in a similar education program within the last 3 months\n* Presence of terminal illness",{"count":5,"type":23},[26],"This randomized controlled trial aims to evaluate the effect of education based on the Pecha Kucha presentation technique on fluid and dietary adherence in patients undergoing hemodialysis. Patients receiving hemodialysis often experience difficulties in adhering to fluid and dietary restrictions, which may lead to adverse clinical outcomes.\n\nThe Pecha Kucha technique is a structured, visually supported presentation format designed to improve understanding and retention of information. In this study, patients in the intervention group will receive education using the Pecha Kucha method, while the control group will receive standard education routinely provided in the dialysis unit.\n\nThe study will assess whether this innovative educational approach improves adherence to treatment and clinical parameters. The findings are expected to contribute to improving patient education strategies in hemodialysis care.",[30,332],"Chronic Kidney Disease",[334,30,335,336,337,332,338],"Pecha Kucha","Patient Education","Fluid Restriction","Dietary Adherence","Nursing Education","2026-04-02",{"date":341,"type":46},"2026-04-08",{"date":343,"type":23},"2026-04",{"date":345,"type":23},"2027-03",{"name":347,"class":53},"Büşra Ceren DEMİREL YILDIZ",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":233,"sex":18,"minAge":19,"maxAge":120,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":89},"100632377","the-effect-of-progressive-muscle-relaxation-exercises-on-depression-and-fatigue-in-patients-receiving-hemodialysis-treatment-a-randomized-controlled-trial-100632377","NCT07512895","The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\nScoring 4 or above on the First-Level Beck Depression Inventory\n\nPatients who regularly receive hemodialysis treatment\n\nIndividuals who are cognitively capable of understanding the exercise instructions\n\nIndividuals who voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\nIndividuals diagnosed with a psychiatric disorder (e.g., major depression, bipolar disorder, schizophrenia, etc.)\n\nIndividuals who are physically unable to perform relaxation exercises due to musculoskeletal disorders\n\nIndividuals who have previously participated regularly in relaxation therapy, yoga, meditation, or similar practices\n\nIndividuals who cannot follow instructions due to hearing, visual, or cognitive impairments\n\nIndividuals who are simultaneously participating in another psychosocial or physical intervention program\n\n\\-",{"count":236,"type":23},[26],"This study aims to evaluate the effects of progressive muscle relaxation exercises on depression and fatigue levels in patients undergoing hemodialysis treatment. Progressive muscle relaxation is applied as an individualized non-pharmacological intervention, and its potential contribution to psychological well-being is investigated. The study seeks to determine whether regular relaxation exercises can reduce depressive symptoms, alleviate fatigue, and improve overall emotional well-being in hemodialysis patients. Findings from this research are expected to provide evidence for the use of relaxation-based interventions as supportive care methods in the management of psychological symptoms associated with chronic kidney disease and hemodialysis.",[358,30],"Hemodialysis Complication",[360,30,361,362],"Depression","Progressive Muscle Relaxation Exercises","Fatigue",{"date":364,"type":46},"2026-04-06",{"date":366,"type":46},"2025-12-01",{"date":246,"type":23},{"name":369,"class":53},"Istanbul Aydın University",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":24,"phases":380,"briefSummary":381,"conditions":382,"keywords":387,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":54},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin",{"count":379,"type":23},15,[26],"People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[383,384,215,385,30,386],"End Stage Renal Disease (ESRD)","Chronic Kidney Disease on Hemodialysis","Uremia; Chronic","Hemodiafiltration",[388,389,390,391,392,393,394,395,396],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","2026-03-23",{"date":399,"type":46},"2026-03-24",{"date":343,"type":23},{"date":402,"type":23},"2029-12",{"name":404,"class":53},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":233,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":415,"conditions":416,"keywords":420,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":427,"locationsCount":4},"100626595","a-survey-for-patients-and-caregivers-aiming-to-understand-and-improve-the-care-of-patients-at-high-risk-of-transfer-from-peritoneal-dialysis-to-hemodialysis-100626595","NCT07437677","A Survey for Patients and Caregivers Aiming to Understand and Improve the Care of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis:","Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis - Phase 2 (Survey)","ULIFT-PD","Inclusion Criteria:\n\n1. Adult (≥18 years)\n2. One of the following:\n\n   * Patient who experienced a PD-to-HD transition in past 12 months\n   * Patient currently receiving peritoneal dialysis\n   * Caregiver (self-defined, including spouses, family members, or friends) of individuals meeting the above criteria\n3. Able to read English or French\n4. Able to complete the survey in paper or web-based format\n5. Able to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Unable to provide consent",{"count":414,"type":23},200,"Home dialysis is encouraged in Canada and peritoneal dialysis is the most common home dialysis method. However, many patients discontinue peritoneal dialysis, often transferring to hemodialysis. Despite the frequency of this transition, little is known about its impact on patients.\n\nOverall, the UPLIFT-PD program aims to fill this gap by studying the transition from peritoneal dialysis to hemodialysis. The specific goal of this mixed methods sub-study is to conduct a national survey to ask patients and caregivers about priorities and preferences when they anticipate a transfer from peritoneal dialysis to hemodialysis. This survey will be co-created by patient-partners and dialysis experts.\n\nResults from this survey will then be used in other phases of UPLIFT-PD program, detailed in other registrations, which will support people facing a transition from peritoneal dialysis to hemodialysis..",[417,30,418,419],"Peritoneal Dialysis (PD)","Kidney Replacement Therapy","Transition",[421],"Transfer to hemodialysis","2026-02-24",{"date":424,"type":46},"2026-02-27",{"date":50,"type":23},{"date":402,"type":23},{"name":428,"class":53},"Ciusss de L'Est de l'Île de Montréal",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":437,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":440,"briefSummary":441,"conditions":442,"keywords":446,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":140},"100614390","hemodiafiltration-versus-hemodialysis-in-older-people-100614390","NCT07278973","Hemodiafiltration Versus Hemodialysis in Older People","HemoDiafiltration Versus HemoDialysis in OLDER People: a Randomized, Multicenter, Crossover, Pragmatic Clinical Trial","HD-OLDER","Inclusion Criteria:\n\n* Signed and dated informed consent\n* Age \\>84 years\n* Diagnosed with kidney failure\n* On maintenance hemodialysis \\>3months\n* Willing to have a dialysis session of 3.5 to 4-hour duration, three times a week\n* Has a reliable vascular access\n* Is covered by the health insurance\n\nExclusion Criteria:\n\n* Patients with cognitive impairment (assessed with a mini-test if needed)\n* Hospitalized at inclusion\n* Have difficulties with French speaking\n* Terminally ill with life expectancy\\\u003C3 months\n* With active cancer","85 Years",{"count":439,"type":23},62,[26],"This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF).\n\nPatients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his\u002Fher own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis.\n\nThese two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.",[30,386,443,444,445],"Fatigue Symptom","Quality of Life of Patients","Older People",[30,386,447,362,448,449],"Older people","Patient reported outcome","Dialysis recovery time","2026-02-20",{"date":452,"type":46},"2026-02-23",{"date":454,"type":23},"2026-02-19",{"date":456,"type":23},"2026-12-19",{"name":458,"class":53},"AUB Santé",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":467,"enrollmentInfo":468,"targetDuration":4,"studyType":24,"phases":470,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":54},"100624662","autogenic-relaxation-and-murottal-therapy-in-hemodialysis-patients-100624662","NCT07412548","Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients","The Effectiveness of Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy on Anxiety, Sleep Quality, and Hemodynamic Parameters in Hemodialysis Patients","AR-MHD","Inclusion Criteria:\n\n1. Patients diagnosed with stage V chronic kidney disease.\n2. Undergoing scheduled hemodialysis at least twice a week for 6 weeks.\n3. Outpatients and aged 18-65 years.\n4. Muslim.\n5. Cooperative and able to communicate verbally.\n6. Willing to be a respondent by signing an informed consent form.\n\nExclusion Criteria:\n\n1. Having a severe heart condition or an unstable critical condition.\n2. Having a severe psychiatric disorder (schizophrenia, major depression).\n3. Having a cognitive, hearing, or speech disorder that impedes communication.\n4. Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.","65 Years",{"count":469,"type":23},76,[26],"This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.",[473,474,30],"Chronic Kidney Disease Stage V","End-Stage Renal Disease",[476,477,478,127,479],"Autogenic Relaxation","Murottal Therapy","Anxiety","Hemodynamics","2026-02-11",{"date":482,"type":46},"2026-02-17",{"date":484,"type":23},"2026-03-01",{"date":43,"type":23},{"name":487,"class":53},"Universitas Muhammadiyah Surakarta",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":24,"phases":496,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":54},"100571947","phase-3-therapeutic-effect-of-manuka-honey-oral-rinse-in-periodontitis-patients-undergoing-hemodialysis-100571947","NCT06726876","Therapeutic Effect of Manuka Honey Oral Rinse in Periodontitis Patients Undergoing Hemodialysis","Inclusion Criteria:\n\n* Both genders, aged above 18 years.\n* All patients must be clinically diagnosed of ESRD undergoing hemodialysis.\n* All patients must have a periodontal disease.\n* Patients must be able to make reliable decision or communications.\n\nExclusion Criteria:\n\n* Smoking, Alcohol.\n* Patient with history of any serious illness as malignancy, who undergo kidney transplant.\n* Patients with any autoimmune disease.\n* Vulnerable groups such as pregnant females, prisoners, mentally and physically handicapped individuals.\n* Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation.",{"count":495,"type":23},150,[497],"PHASE3","Chronic Kidney Disease (CKD) has a strong association with chronic periodontitis, an oral disease causing tooth loss linked to inflammation and malnutrition. While periodontitis affects 12.7% of the general population, its prevalence can rise to 39% in certain racial groups, and a dose-response relationship exists with CKD. End Stage Renal Disease (ESRD) patients show a prevalence of periodontitis ranging from 29% to 85.6%. Uremia, immunosuppression, and vitamin D deficiency are suggested factors in the etiology of periodontitis in CKD patients, with uremic toxins potentially altering the oral ecosystem.\n\nPeriodontitis involves bacterial biofilm and Gram-negative anaerobes as primary etiological factors. The main treatment goal is to reduce periodontal pathogens and control inflammation, with non-surgical periodontal therapy (NSPT) being the standard. Although various adjuncts like antibiotics and antiseptics are suggested, recent guidelines only recommend certain locally administered agents and systemic antibiotics for specific groups due to increasing bacterial resistance.\n\nAlternative treatments like honey have gained interest, particularly Manuka honey, known for its antibacterial properties against antibiotic-resistant bacteria. This honey's effectiveness is due to its high sugar concentration, low pH, and formation of hydrogen peroxide. Manuka honey's unique component, methylglyoxal (MGO), is a potent bactericide, virucide, and fungicide, linked to its Non-Peroxide Activity (NPA) and Unique Manuka Factor (UMF) rating. MGO also has immunomodulatory effects beneficial for wound healing and tissue regeneration.\n\nPrevious studies show Manuka honey as a promising adjunct in NSPT, improving outcomes significantly without adverse effects. Ongoing research aims to evaluate its effects in ESRD patients on hemodialysis, focusing on clinical attachment levels, other periodontal parameters, and FGF 21 levels in gingival crevicular fluid.",[500,30],"Periodontitis",[502,503,504,186],"Manuka honey","fibroblast growth factor-21","periodontitis","2025-12-26",{"date":507,"type":46},"2025-12-31",{"date":509,"type":46},"2024-10-01",{"date":511,"type":23},"2025-12-30",{"name":513,"class":53},"Ain Shams University",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":538},"100414067","a-study-to-evaluate-the-safety-and-effectiveness-of-the-innavasc-arteriovenous-graft-for-hemodialysis-access-in-patients-with-end-stage-renal-disease-100414067","NCT04671771","A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease","Inclusion Criteria:\n\nPre-Operative Inclusion Criteria:\n\nPatients must meet the following criteria at screening in order to be scheduled for a procedure and potentially enrolled in the study:\n\n1. Patients with ESRD whose next most appropriate option for AV access is placement of an AV graft to start or maintain hemodialysis therapy;\n2. Age 18 to 90 years old, inclusive;\n3. Suitable anatomy for implantation of upper arm \"straight\" or looped graft, or forearm looped graft (graft not to cross the bend of the elbow);\n4. Ability to continue or commence antiplatelet therapy post graft implant (anticoagulation medication is acceptable if the subject is required to take an anticoagulant for a baseline medical condition);\n5. Able and willing to give informed consent;\n6. Anticipated life expectancy of at least 1 year.\n\nIntra-Operative Inclusion Criteria:\n\nBoth vessels have been exposed and are deemed appropriate for implantation (i.e., based on the surgeon's opinion, artery is of adequate size, has adequate pulse to support AV access flow, is without significant calcification, and is safely clampable; and the vein is of adequate size, free of localized sclerosis, and is free of immediate outflow obstruction).\n\nPre-Operative Exclusion Criteria:\n\nPatients will be excluded from the study at screening if they exhibit any of the following exclusion criteria:\n\n1. History or evidence of severe cardiac disease (i.e., debilitating heart failure, or high risk of MI) in the opinion of the investigator which may preclude participation in and completion of the study;\n2. Uncontrolled diabetes in the opinion of the investigator (i.e., multiple recent diabetes related hospitalizations);\n3. For upper arm straight configuration, an antecubital fossa crease to axillary crease distance \\\u003C 18 cm;\n4. History or evidence of severe peripheral arterial disease in the extremity selected for implant (i.e., arterial inflow insufficient to support hemodialysis access);\n5. Known or suspected central vein stenosis or obstruction on the side of planned graft implantation;\n6. Baseline hypotension or history of frequent hypotensive episodes during dialysis that, in the opinion of the investigator, puts the patient at increased risk of graft thrombosis;\n7. Uncontrolled hypertension, per the opinion of the investigator (i.e., recent history of recurrent hospitalizations for hypertensive related illness);\n8. Baseline hemoglobin \\\u003C7 g\u002FdL;\n9. Baseline platelet count \\\u003C50,000 or \\>500,000 cells\u002Fmm3;\n10. Documented history of stroke within 6 months prior to enrollment;\n11. Treatment with any investigational drug or device within 30 days prior to enrollment;\n12. Female patients who are pregnant, intending to become pregnant, nursing or intending to breastfeed during the study (pregnancy test may only be omitted, if patient is post-menopausal or has a documented history of hysterectomy or permanent sterilization);\n13. History of cancer with active disease or treatment within the previous year, except for non-invasive basal or squamous cell carcinoma of the skin;\n14. Immunodeficiency including documented history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) or patients receiving immunosuppressive therapy for treatment of an acute inflammatory event or autoimmune flare. Chronic immunosuppressive therapy is acceptable;\n15. Documented or suspected hypercoagulable condition;\n16. Bleeding diathesis, other than that associated with ESRD;\n17. Documented history of heparin-induced thrombocytopenia (HIT);\n18. Active local or systemic infection as documented from the medical history or bloodwork\u002Fblood culture data. If the infection resolves, the subject must be at least one-week post resolution of that infection before implantation;\n19. Scheduled renal transplant within 6 months;\n20. Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and effectiveness of the IG;\n21. Patient is unable or unwilling to complete all required follow-up assessments and questionnaires.","90 Years",{"count":522,"type":23},133,[26],"The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are:\n\nPrimary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months.\n\nPrimary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months.\n\nParticipants will be asked to sign an informed consent form. Once enrolled, they will be assessed to receive the study graft implant and asked to participate in periodic follow-up visits and assessments through 2 years following implant.",[383,526,527,30],"Kidney Failure","Chronic Renal Disease","2025-12-18",{"date":530,"type":46},"2025-12-22",{"date":532,"type":46},"2020-12-03",{"date":534,"type":23},"2029-07-01",{"name":536,"class":537},"W.L.Gore & Associates","INDUSTRY",21,{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":54},"100591546","physical-activity-for-haemodialysis-patients-evaluation-of-personalised-support-by-an-adapted-physical-activity-teacher-and-an-advanced-practice-nurse-100591546","NCT06981832","Physical Activity for Haemodialysis Patients: Evaluation of Personalised Support by an Adapted Physical Activity Teacher and an Advanced Practice Nurse","HE-MOVE","Pre-Inclusion Criteria:\n\n* Patient over 18 years of age\n* Patient who has been receiving haemodialysis for less than a year\n* Patient with medical prescription for physical activity\n* Patient able to understand the protocol and having given consent to participate in the research,\n* Patient affiliated to the social security system or entitled beneficiary\n\nInclusion Criteria:\n\n* Patient with physical activity considered low or moderate according to the IPAQ questionnaire\n\nExclusion Criteria:\n\n* Patients with medical contraindications to adapted physical activity\n* Patients with a lower limb amputation\n* Patients undergoing peritoneal dialysis\n* Patient with a peritoneal dialysis project\n* Patient participating in another clinical research protocol with an impact on the research objectives\n* Patient already randomised in the study\n* Patient who is pregnant, parturient, breastfeeding or able to procreate without effective contraception at the time of inclusion\\*.\n* Patients under guardianship, curatorship or deprived of liberty\n* Patient under activated future protection mandate\n* Patient under family habilitation\n* Patient under court protection",{"count":5,"type":23},[26],"Physical activity is defined as 'any bodily movement produced by skeletal muscles that results in an energy expenditure greater than that of the resting metabolism'. Physical activity includes 'activities of daily living, physical exercise and sporting activities'.\n\nThe scientific community is agreed in recognising the benefits of physical activity, both in healthy individuals and in those suffering from chronic diseases.\n\nWith this in mind, the law of 2 March 2022 allows doctors to prescribe Adapted Physical Activity.\n\nIn the case of chronic renal failure, there are a number of factors that can limit physical activity in haemodialysis patients, such as anaemia, nutritional status and post-dialysis fatigue.\n\nHowever, the risks associated with a sedentary lifestyle play a role in the development of chronic disease, in particular hypertension and diabetes. The benefits of physical activity have been widely identified in chronic renal failure, particularly in terms of cardiovascular and muscular function.\n\nMore generally, physical activity has a positive impact on physical, psychological and social quality of life (increase in overall quality of life score, improved sleep, reduced pain, etc.).\n\nPhysical activity should therefore be encouraged in patients with chronic renal failure, whether on dialysis or not, whatever their age.\n\nThe aim of this study is to assess whether individualised support (from an advanced practice nurse and an adapted physical activity teacher) improves the practice of physical activity at home in patients who have been on haemodialysis for less than a year, and whether this improvement is sustainable over time.",[30],"2025-12-17",{"date":552,"type":46},"2025-12-23",{"date":554,"type":46},"2025-10-28",{"date":556,"type":23},"2028-04",{"name":558,"class":53},"Centre Hospitalier Departemental Vendee",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":24,"phases":568,"briefSummary":569,"conditions":570,"keywords":577,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":54},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469","NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy",{"count":236,"type":23},[26],"Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[571,385,572,573,30,574,575,576],"CKD (Chronic Kidney Disease) Stage 5D","Uremic; Toxemia","Inflammation Chronic","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[578,579,580],"Program dialysis","Sorption","Complications of program dialysis","2025-12-03",{"date":583,"type":46},"2025-12-10",{"date":585,"type":46},"2025-06-01",{"date":43,"type":23},{"name":588,"class":53},"Botkin Hospital",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":24,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":54},"100613859","the-effect-of-home-based-walking-on-symptoms-and-health-profile-of-hemodialysis-patients-100613859","NCT07272070","The Effect of Home-Based Walking on Symptoms and Health Profile of Hemodialysis Patients","The Effect of Home-Based Walking on Symptoms and Health Profile of Hemodialysis Patients:Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients who agreed to participate in the research during the data collection process,\n* Over 18 years of age,\n* Speak and understand Turkish,\n* Are at least literate,\n* Can perform daily living activities independently,\n* Own a smartphone.\n\nExclusion Criteria:\n\n* Do not have sufficient cognitive ability,\n* Have arthritic or orthopedic problems requiring assistance with walking,\n* Have significant visual or hearing impairments,\n* Walk regularly,\n* Have a hemoglobin level \\\u003C8 mg\u002Fdl,\n* Have Stage IV of New York heart failure.",{"count":597,"type":23},24,[26],"This study aims to evaluate the effect of 8 weeks of home-based moderate-speed walking on hemodialysis symptoms and health profile while patients are receiving hemodialysis treatment.\n\nDue to permanent deterioration in kidney function, patients need hemodialysis treatment, which is the most commonly used treatment method among renal replacement therapies. Hemodialysis treatment causes a series of physical and psychological problems. Problems such as hypotension, headache, nausea, muscle cramps, itching and pain are physical problems, while depression, anxiety, cognitive disorders and stress are psychological problems. In addition, it has been reported that long-term hemodialysis treatment and all the resulting problems increase the tendency to a sedentary lifestyle in this patient group, leading to a decrease in physical function and activity, and indirectly to a low quality of life and low survival rates. For this reason, hemodialysis patients have difficulty meeting their daily activities and needs, and their dependency and healthcare burden increase. Adopting a sedentary lifestyle by these patients prevents them from managing both the physical and psychological problems of hemodialysis and their conditions such as hypertension and diabetes mellitus, and causes the disease to progress. Physical exercises, which are considered among the useful therapeutic suggestions in addition to pharmacological treatments in the management of the negative situations that arise, are considered as an easy, useful and effective intervention method. Kidney Disease: Improving Global Outcomes (KDIGO) recommends 30 minutes of moderate-intensity physical exercise at least 5 days a week. Additionally, it should not be overlooked that whether patients have places to do physical activity and what their facilities are are a detail that should be questioned by health professionals. Patients without suitable accommodations should be encouraged to engage in physical activity, especially in indoor spaces like home. Home-based walking exercise is known to be easy, inexpensive, and safe, and is also advantageous when the weather is not favorable. When we examined the studies in which home-based walking exercise was performed, it was determined that its effect on functional capacity was generally investigated, but its effect on the health outcomes and symptoms of patients receiving hemodialysis treatment was not evaluated. There was no evidence that home-based walking exercise had any effect on symptoms in patients receiving HD treatment. Therefore, it was planned to conduct a study to evaluate whether home-based walking exercise has an effect on patient health outcomes.",[601,30,602,603],"Muscle Cramp","Vibration","Stretching","2025-11-26",{"date":606,"type":46},"2025-12-09",{"date":608,"type":23},"2025-12-15",{"date":43,"type":23},{"name":611,"class":53},"Figen Akay",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":619,"maxAge":234,"enrollmentInfo":620,"targetDuration":4,"studyType":24,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":54},"100598853","aerobic-exercises-and-hemodialysis-patients-100598853","NCT07076888","Aerobic Exercises and Hemodialysis Patients","Impact of Aerobic Exercises on Serum Uric Acid Levels in Hemodialysis Patients","Inclusion Criteria:\n\n1. Hemodialysis patients aged 40-60years\n2. Patients are medically stable and able to participate in physical activity.\n3. Participants are able to understand the commands.\n4. Participants must be stable on hemodialysis for at least 3 months.\n\nExclusion Criteria:\n\n1. Patients with significant cardiovascular or respiratory diseases, or other conditions that could impair their ability to exercise.\n2. Severe cognitive impairment or psychiatric conditions that could interfere with study participation.\n3. patients with acute medical conditions.","40 Years",{"count":621,"type":23},32,[26],"Patients undergoing hemodialysis (HD) frequently exhibit elevated serum uric acid (SUA) levels, which are associated with cardiovascular risks, joint issues, and diminished quality of life (QoL). Aerobic exercise has been shown to improve cardiovascular health and reduce SUA levels in various populations, suggesting potential benefits for HD patients.\n\nObjective: This study aimed to investigate the impact of aerobic exercise on serum uric acid (SUA) levels, functional capacity, and quality of life (QoL) in patients undergoing hemodialysis (HD).\n\nMethods: This randomized controlled trial will recruit 32 participants, aged 40-60, undergoing HD. The intervention group (Group A) will participate in a structured 6-week aerobic exercise program, while the control group (Group B) will receive only conventional physical therapy. Pre- and post-intervention assessments included SUA levels, the Six-Minute Walk Test (6MWT), and the Kidney Disease Quality of Life Short Form (KDQOL-SF™)",[30],[626,186,627,628],"Aerobic exercise","serum uric acid","quality of life","2025-11-15",{"date":631,"type":46},"2025-11-19",{"date":633,"type":46},"2025-08-01",{"date":635,"type":23},"2025-12-20",{"name":637,"class":53},"Cairo University",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":24,"phases":647,"briefSummary":648,"conditions":649,"keywords":651,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":54},"100608820","effect-of-modifying-magnesium-concentration-in-citrate-enriched-dialysate-on-hemodialysis-associated-thromboinflammation-100608820","NCT07206524","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation: a Local Pilot OMAGOD Plus Trial","pilot OMAGOD +","Inclusion Criteria:\n\n* Participants to the OMAGOD pilot trial\n\nExclusion Criteria:\n\n* Patients who are not participating in the OMAGOD pilot trial",{"count":379,"type":23},[26],"This clinical trial investigates whether the composition of dialysate influences hemodialysis-associated thromboinflammation. Specifically, it evaluates the effects of magnesium concentration and acid type in dialysate on immune cell activation and thromboinflammatory responses.\n\nPatients participating to the multicentric pilot OMAGOD trial will be invited to participate to this monocentric plus study.\n\nIn the pilot OMAGOD trial, participants will undergo standard hemodialysis (3 sessions\u002Fweek, 4 hours each) and receive three different dialysate compositions in a crossover design. Each treatment phase lasts two weeks (six sessions).\n\nFor the local plus study, during selected sessions (3 per patient - midweek hemodialysis session of the last week of a treatment period), blood samples will be collected (at baseline, hourly, and at the end of dialysis) and additionally, after each session, the used dialysis circuit will be rinsed to recover adherent cells.\n\nThe study aims to:\n\n* Assess whether the dialysate composition influences leukocyte and platelet activation .\n* Evaluate whether the dialysate composition influences neutrophil extracellular trap (NET) formation.\n* Identify novel biomarkers of thromboinflammation using transcriptomic analysis of immune cells.",[30,650,358,383],"Thromboinflammation",[186,652,653,654,655,656],"thromboinflammation","neutrophil extracellular trap formation","dialysate composition","cellular activation","transcriptome analysis","2025-11-14",{"date":659,"type":46},"2025-11-17",{"date":661,"type":46},"2025-06-05",{"date":663,"type":23},"2026-12",{"name":665,"class":53},"Universitair Ziekenhuis Brussel",{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":673,"enrollmentInfo":674,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":675,"conditions":676,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":682,"leadSponsor":684,"locationsCount":4},"100609162","prevalence-of-latent-tuberculosis-infection-among-hemodialysis-patients-100609162","NCT07210970","Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients","Study of The Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients Using Tuberculin Skin Test at Sohag University Hospital","Inclusion Criteria:\n\nAge ≥ 18 years Patients on regular hemodialysis Able and willing to provide informed consent\n\n\\-\n\nExclusion Criteria:\n\n* active TB patients","100 Years",{"count":414,"type":23},"This observational cross-sectional study aims to determine the prevalence of latent tuberculosis infection (LTBI) among patients undergoing regular hemodialysis at Sohag University Hospital, using the tuberculin skin test (TST). Identifying the burden of LTBI in this high-risk population will help guide early detection and preventive strategies",[677,383,30],"Latent Tuberculosis Infection","2025-09-30",{"date":680,"type":46},"2025-10-07",{"date":366,"type":23},{"date":683,"type":23},"2027-12-20",{"name":685,"class":53},"Sohag University"]